GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

The UPLC system was configured with an Acquity Premier Oligonucleotide C18 column (1.7 µm, 2.1 × 50 mm). The aqueous and ...

Researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

A biochemical breakthrough using simple carbon atoms, by Ken Yamada, Ph.D., and Anastasia Khvorova, Ph.D., has dramatically improved the stability and efficacy of a potential oligonucleotide ...

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...

siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...